Sitravatinib

Sitravatinib.svg

Sitravatinib is a tyrosine kinase inhibitor (TKI) that is being investigated for its potential use in the treatment of various types of cancer. It is a small molecule inhibitor that targets multiple receptor tyrosine kinases (RTKs), which are involved in the growth and spread of cancer cells.

Mechanism of Action

Sitravatinib works by inhibiting the activity of several RTKs, including TAM receptors (Tyro3, Axl, and Mer), VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), and KIT (stem cell factor receptor). By blocking these pathways, sitravatinib can reduce tumor growth, angiogenesis (formation of new blood vessels), and metastasis (spread of cancer).

Clinical Development

Sitravatinib is currently being evaluated in clinical trials for its efficacy and safety in treating various cancers, including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. It is often studied in combination with other therapies, such as immune checkpoint inhibitors like nivolumab and pembrolizumab, to enhance its anti-tumor effects.

Potential Indications

• Non-small cell lung cancer (NSCLC)
• Renal cell carcinoma (RCC)
• Melanoma
• Other solid tumors

Side Effects

As with other TKIs, sitravatinib may cause a range of side effects. Common side effects include:

• Fatigue
• Nausea
• Diarrhea
• Hypertension
• Rash

Research and Future Directions

Ongoing research is focused on understanding the full potential of sitravatinib in cancer therapy, including its use in combination with other treatments and its effectiveness in different cancer types. Future studies aim to identify biomarkers that can predict response to sitravatinib and to optimize dosing regimens to maximize its therapeutic benefits while minimizing side effects.

See Also

• Tyrosine kinase inhibitor
• Non-small cell lung cancer
• Renal cell carcinoma
• Melanoma
• Immune checkpoint inhibitor